Cross-species malaria immunity induced by chemically attenuated parasites

Journal of Clinical Investigation

Volumn 123, Issue 8, 2013, Pages 3353-3362

  Good, Michael F ^a   Reiman, Jennifer M ^a   Rodriguez, I Bibiana ^a   Ito, Koichi ^a   Yanow, Stephanie K ^b   El Deeb, Ibrahim M ^a   Batzloff, Michael R ^a   Stanisic, Danielle I ^a   Engwerda, Christian ^c   Spithill, Terry ^d   Hoffman, Stephen L ^e   Lee, Moses ^f   McPhun, Virginia ^a  

^a GRIFFITH UNIVERSITY   (Australia)

^b UNIVERSITY OF ALBERTA   (Canada)

^c QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^d LA TROBE UNIVERSITY   (Australia)

^e SANARIA INC   (United States)

^f HOPE COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CENTANAMYCIN; DNA; INDOLE DERIVATIVE; TAFURAMYCIN A; UNCLASSIFIED DRUG; VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD SAMPLING; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DNA REPLICATION; ERYTHROCYTE MEMBRANE; FEMALE; IMMUNITY; LYMPHOCYTE CULTURE; MALARIA; MICROBIAL ATTENUATION; MOUSE; NONHUMAN; PLASMODIUM CHABAUDI; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; VACCINATION;

EID: 84881245385     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI66634     Document Type: Article

References (46)

1. Stevenson MM, Riley EM. Innate immunity to malaria. Nat Rev Immunol. 2004;4(3):169-180.
2. Langhorne J, Ndungu F, Sponaas A, Marsh K. Immunity to malaria: more questions than answers. Nat Immunol. 2008;9(7):725-732.
3. Crompton PD, Pierce SK, Miller LH. Advances and challenges in malaria vaccine development. J Clin Invest. 2010;120(12):4168-4178.
4. Genton B, et al. A recombinant blood-stage malaria vaccine reduces Plasmodium falciparum density and exerts selective pressure on parasite populations in a phase 1-2b trial in Papua New Guinea. J Infect Dis. 2002;185(6):820-827.
5. Sagara I, et al. A randomized controlled phase 2 trial of the blood stage AMA1-C1/Alhydrogel malaria vaccine in children in Mali. Vaccine. 2009;27(23):3090-3098.
6. Ogutu BR, et al. Blood stage malaria vaccine eliciting high antigen-specific antibody concentrations confers no protection to young children in Western Kenya. Plos One. 2009;4(3):e4708.
7. Barry AE, Schultz L, Buckee CO, Reeder JC. Contrasting population structures of the genes encoding ten leading vaccine-candidate antigens of the human malaria parasite, Plasmodium falciparum. PLoS One. 2009;4(12):e8497.
8. Hirunpetcharat C, et al. Complete protective immunity induced in mice by immunization with the 19-kilodalton carboxyl-terminal fragment of the merozoite surface protein-1 (MSP1[19]) of Plasmodium yoelii expressed in Saccharomyces cerevisiae: correlation of protection with antigenspecific antibody titer, but not with effector CD4+ T cells. J Immunol. 1997;159(7):3400-3411.
9. Singh S, et al. Immunity to recombinant plasmodium falciparum merozoite surface protein 1 (MSP1): protection in Aotus nancymai monkeys strongly correlates with anti-MSP1 antibody titer and in vitro parasite-inhibitory activity. Infect Immun. 2006;74(8):4573-4580.
10. Price RN, Tjitra E, Guerra CA, Yeung S, White NJ, Anstey NM. Vivax malaria: neglected and not benign. Am J Trop Med Hyg. 2007;77(6 suppl):79-87.
11. Pombo DJ, et al. Immunity to malaria after administration of ultra-low doses of red cells infected with Plasmodium falciparum. Lancet. 2002;360(9333):610-617.
12. Elliott SR, Kuns RD, Good MF. Heterologous immunity in the absence of variant-specific antibodies after exposure to subpatent infection with blood-stage malaria. Infect Immun. 2005;73(4):2478-2485.
13. Edstein MD, et al. Lengthy antimalarial activity of atovaquone in human plasma following atovaquone- proguanil administration. Antimicrob Agents Chemother. 2005;49(10):4421-4422.
14. Makobongo MO, et al. The purine salvage enzyme hypoxanthine guanine xanthine phosphoribosyl transferase is a major target antigen for cell-mediated immunity to malaria. Proc Natl Acad Sci U S A. 2003;100(5):2628-2633.
15. Xu H, et al. The mechanism and significance of deletion of parasite-specific CD4(+) T cells in malaria infection. J Exp Med. 2002;195(7):881-892.
16. Pinzon-Charry A, et al. Low doses of killed parasite in CpG elicit vigorous CD4+ T cell responses against blood-stage malaria in mice. J Clin Invest. 2010;120(8):2967-2978.
17. Aly AS, Downie MJ, Mamoun CB, Kappe SH. Subpatent infection with nucleoside transporter 1-deficient Plasmodium blood stage parasites confers sterile protection against lethal malaria in mice. Cell Microbiol. 2010;12(7):930-938.
18. Annoura T, et al. Assessing the adequacy of attenuation of genetically modified malaria parasite vaccine candidates. Vaccine. 2012;30(16):2662-2670.
19. Yanow SK, Purcell LA, Lee M, Spithill TW. Genomics- based drug design targets the AT-rich malaria parasite: implications for antiparasite chemotherapy. Pharmacogenomics. 2007;8(9):1267-1272.
20. Purcell LA, Yanow SK, Lee M, Spithill TW, Rodriguez A. Chemical attenuation of Plasmodium berghei sporozoites induces sterile immunity in mice. Infect Immun. 2008;76(3):1193-1199.
21. Purcell LA, Wong KA, Yanow SK, Lee M, Spithill TW, Rodriguez A. Chemically attenuated Plasmodium sporozoites induce specific immune responses, sterile immunity and cross-protection against heterologous challenge. Vaccine. 2008;26(38):4880-4884.
22. Liu SC, et al. Red cell membrane remodeling in sickle cell anemia. Sequestration of membrane lipids and proteins in Heinz bodies. J Clin Invest. 1996;97(1):29-36.
23. Butler NS, et al. Therapeutic blockade of PD-L1 and LAG-3 rapidly clears established bloodstage Plasmodium infection. Nat Immunol. 2012;13(2):188-195.
24. Kumar S, Good MF, Dontfraid F, Vinetz JM, Miller LH. Interdependence of CD4+ T cells and malarial spleen in immunity to Plasmodium vinckei vinckei. Relevance to vaccine development. J Immunol. 1989;143(6):2017-2023.
25. Playfair JH, De Souza JB, Dockrell HM, Agomo PU, Taverne J. Cell-mediated immunity in the liver of mice vaccinated against malaria. Nature. 1979;282(5740):731-734.
26. Dockrell HM, de Souza JB, Playfair JH. The role of the liver in immunity to blood-stage murine malaria. Immunology. 1980;41(2):421-430.
27. Yanow SK, et al. Potent antimalarial and transmission- blocking activities of centanamycin, a novel DNA-binding agent. J Infect Dis. 2008;197(4):527-534.
28. Weiss L, Geduldig U, Weidanz W. Mechanisms of splenic control of murine malaria: reticular cell activation and the development of a blood-spleen barrier. Am J Anat. 1986;176(3):251-285.
29. Alves HJ, Weidanz W, Weiss L. The spleen in murine Plasmodium chabaudi adami malaria: stromal cells, T lymphocytes, and hematopoiesis. Am J Trop Med Hyg. 1996;55(4):370-378.
30. Florens L, et al. A proteomic view of the Plasmodium falciparum life cycle. Nature. 2002; 419(6906):520-526.
31. Stevenson M, Zavala F. Immunology of malaria infections. Parasite Immunology. 2006;28(1-2):1-4.
32. Good MF, Xu H, Wykes M, Engwerda CR. Development and regulation of cell-mediated immune responses to the blood stages of malaria: implications for vaccine research. Annu Rev Immunol. 2005;23:69-99.
33. Urban BC, et al. Plasmodium falciparum-infected erythrocytes modulate the maturation of dendritic cells. Nature. 1999;400(6739):73-77.
34. Sanderson F, Andrews L, Douglas AD, Hunt- Cooke A, Bejon P, Hill AV. Blood-stage challenge for malaria vaccine efficacy trials: a pilot study with discussion of safety and potential value. Am J Trop Med Hyg. 2008;78(6):878-883.
35. McCarthy JS, Good MF. Whole parasite blood stage malaria vaccines: a convergence of evidence. Hum Vaccin. 2010;6(1):114-123.
36. Cheng Q, et al. Measurement of Plasmodium falciparum growth rates in vivo: a test of malaria vaccines. Am J Trop Med Hyg. 1997;57(4):495-500.
37. Lawrence G, et al. Effect of vaccination with 3 recombinant asexual-stage malaria antigens on initial growth rates of Plasmodium falciparum in non-immune volunteers. Vaccine. 2000; 18(18):1925-1931.
38. Hoffman SL, et al. Protection of humans against malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoites. J Infect Dis. 2002;185(8):1155-1164.
39. Epstein JE, et al. Live attenuated malaria vaccine designed to protect through hepatic CD8(+) T cell immunity. Science. 2011;334(6055):475-480.
40. Mueller AK, Labaied M, Kappe SH, Matuschewski K. Genetically modified Plasmodium parasites as a protective experimental malaria vaccine. Nature. 2005;433(7022):164-167.
41. Roestenberg M, et al. Protection against a malaria challenge by sporozoite inoculation. N Engl J Med. 2009;361(5):468-477.
42. Agnandji ST, et al. First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children. N Engl J Med. 2011;365(20):1863-1875.
43. Sato A, et al. A novel class of in vivo active anticancer agents: achiral seco-amino- and secohydroxycyclopropylbenz[ e]indolone (seco-CBI) analogues of the duocarmycins and CC-1065. J Med Chem. 2005;48(11):3903-3918.
44. Howard TT, et al. Novel furano analogues of duocarmycin C1 and C2: design, synthesis, and biological evaluation of seco-iso-cyclopropylfurano[ 2,3-e]indoline (seco-iso-CFI) and secocyclopropyltetrahydrofurano[ 2,3-f]quinoline (seco-CFQ) analogues. Bioorg Med Chem. 2002; 10(9):2941-2952.
45. Chavda S, et al. A novel achiral seco-cyclopropylpyrido[ e]indolone (CPyI) analog of CC-1065 and the duocarmycins: synthesis, DNA interactions, in vivo anticancer and anti-parasitic evaluation. Bioorg Med Chem. 2010;18(14):5016-5024.
46. Grimberg BT, Erickson JJ, Sramkoski RM, Jacobberger JW, Zimmerman PA. Monitoring Plasmodium falciparum growth and development by UV flow cytometry using an optimized Hoechstthiazole orange staining strategy. Cytometry A. 2008;73(6):546-554.